Optimization of Conservative Therapy Approaches for Benign Prostatic Hyperplasia with 5-Alpha Reductase Inhibitors: A Clinical and Morphological Study
January 2012
in “
Курский научно-практический вестник "Человек и его здоровье"
”
New to Finasteride? There is a guide in the encyclopedia. Read the guide → Studysummary In this study, indications for monotherapy with 5-alpha-reductase inhibitors, such as finasteride and herbal drugs, were developed based on clinical and morphological changes in patients with benign prostatic hyperplasia.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study, conducted on 65 patients, aimed to optimize conservative therapy for benign prostatic hyperplasia (BPH) using 5-alpha-reductase inhibitors, specifically finasteride and the herbal extract Serenoarepens. Over 6 months, both treatments significantly improved urinary symptoms and quality of life, with finasteride reducing the International Prostate Symptom Score (IPSS) by 22.2% and quality of life score by 30.2%, while Serenoarepens reduced IPSS by 30% and quality of life score by 18.7%. Both treatments also decreased prostate volume, with finasteride showing an 18.7% reduction and Serenoarepens 18%. The study highlighted the safety and tolerability of these treatments, although some finasteride users reported temporary sexual dysfunction. The findings supported the use of 5-alpha-reductase inhibitors in managing BPH, with finasteride showing notable morphological changes in prostate tissue, and emphasized a multidisciplinary approach in treatment selection.
